Availity® Co-Honored with 2025 KLAS Points of Light Awards for Care Gap Closure and Payer-to-Payer Data Exchange
JACKSONVILLE, Fla., May 21, 2025--(BUSINESS WIRE)--Availity, the nation's largest real-time health information network, has been twice named a 2025 Points of Light Award recipient by KLAS Research.
These recognitions celebrate two case studies with leading national health plans. One award recognizes Availity's efforts to improve clinical data exchange and provider engagement through innovative digital tools within Availity's multi-payer provider portal, designed to streamline quality and risk care gap reporting and closure.
Together, the organizations replaced time-consuming, paper-based processes with integrated, electronic solutions that notify providers of quality and risk documentation gaps and allow them to submit the required information quickly and securely within their existing workflows to document patient care gap closure and support value-based care initiatives.
The other award recognizes Availity's work with three national payer organizations to enhance payer-to-payer data exchange by developing a centralized connectivity hub, to accelerate interoperability mandate compliance and facilitate more seamless, interoperable exchange of member health plan data as they transition across plans, ultimately resulting in reducing care gaps, administrative inefficiencies, and data fragmentation during member transitions between health plans.
This innovative solution enables multiple payer organizations to reduce the need for establishing multiple end-point connections with health plans, improves continuity of care, and supports compliance with upcoming CMS interoperability mandates.
"Availity is proud to be recognized by KLAS, which embodies our shared commitment to reducing administrative burden in healthcare, enhancing the provider experience, and advancing healthcare interoperability," said Ashley Basile, Clinical Chief Product Officer, Availity. "Through our digital care gap tools, we are empowering providers with a unified, multi-payer digital workflow to improve quality reporting and care outcomes. At the same time, our payer-to-payer data exchange initiative is helping health plans support better continuity of care for members as they transition between plans and support CMS mandate compliance."
Availity Digital Care Gap Tools
Key results from the digital care gap reporting collaboration include 34,000+ quality measures submitted electronically through Availity's multi-payer portal as of October 2024 (an average of two care gaps closed per form submitted during the measurement period). In addition:
70% of network providers now have access to Availity's digital care gap tools, up from just 25%
In addition to improved HEDIS and Stars performance, considerable financial savings were generated through:
Reduction in need for manual retrieval of medical records to support submissions; estimated $15 - $25 saved per medical record no longer required
Reduction in estimated $10,000 in print, mail, and handling costs per quarterly mailing no longer required ($40,000 annually for each quarterly mailer)
Payer-to-Payer Data Exchange
Key results from the payer-to-payer collaboration include:
Successful implementation of a centralized hub-and-spoke model for secure payer-to-payer data exchange
Reduced onboarding time and administrative complexity for participating payer organizations
Capture of long-term cost savings and improved data accuracy via a platform that delivers multi-payer connectivity efficiencies and economies of scale
Strengthened compliance readiness for CMS interoperability mandates effective January 2027
Enhanced continuity of care during member transitions between health plans through faster, standardized data sharing
The KLAS Points of Light annual awards celebrate success stories achieved by payers, healthcare organizations, and healthcare IT companies whose partnerships focus on reducing costs and inefficiencies while striving to improve the patient experience. The awards will be presented at the KLAS K2 Collaborative Summit, May 20–22 in Salt Lake City.
About Availity
Availity is the trusted partner for organizations seeking to realize the greatest value from clinical, administrative, and financial data. Positioned at the nexus of provider, health plan, and consumer health information, Availity develops scalable, innovative solutions for healthcare data acquisition, standardization, transparency, automation, and exchange among health plans, providers, and technology partners. As one of the nation's largest health information networks, Availity facilitates billions of clinical, administrative, and financial transactions annually. Learn more at www.availity.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521803769/en/
Contacts
Media Contact: fuocoavaility@growwithfuoco.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Yahoo
2 days ago
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio